DNLI Denali Therapeutics Inc.
$21.09▼ -1.45%
Healthcare
Other
After hours
$22.11▲ +4.82%
Sep 11, 7:59 PM ET
Volume 1.24M
Avg Volume (10D) 1.29M
Key Metrics & Fundamentals
Market Cap
$3.37B
P/E Ratio
–
Div Yield
–%
52W Range
12.58 - 27.30
% vs 50 MA
-12.46%
% vs 200 MA
0.79%
RSI-14
28.7
MACD Histogram
-0.3500
Beta (1Y vs SPY)
1.52
Free Cash Flow
-$126.61M
Gross Rev
$3.60M
Gross Profit
$3.51M
EBITDA
-$126.06M
COGS
$93,000
Operating Exp
$134.05M
Operating Income
-$130.54M
EBIT
-$130.54M
Pretax Income
-$127.55M
Net Income
-$127.55M
EPS (Diluted)
-0.68
Price & Volume History
Loading chart…
Recent News
Denali Therapeutics Insider Sold Shares Worth $261,929, According to a Recent SEC Filing
MT Newswires · Sep 4, 2026 9:12 PM
B. Riley Adjusts Denali Therapeutics Price Target to $35 From $30, Maintains Buy Rating
MT Newswires · Aug 25, 2026 11:55 AM
DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?
Zacks · Aug 20, 2026 4:20 PM
Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?
Zacks · Aug 20, 2026 2:12 PM
Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 13, 2026 10:32 PM
UBS Adjusts Price Target on Denali Therapeutics to $34 From $25, Maintains Buy Rating
MT Newswires · Aug 7, 2026 2:28 PM
Denali Therapeutics Inc. Q2 2026 Earnings Call Summary
Moby · Aug 7, 2026 12:30 PM
Wedbush Adjusts PT on Denali Therapeutics to $27 From $26, Maintains Outperform Rating
MT Newswires · Aug 7, 2026 10:33 AM
Denali Therapeutics Q2 Earnings Call Highlights
MarketBeat · Aug 7, 2026 1:03 AM
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates
Zacks · Aug 6, 2026 9:40 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See DNLI's money flow as a full page
Social Sentiment
Avg -0.60 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.